# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio (NASDAQ:ETNB) with a Overweight and maintains $29 price target.
Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio (NASDAQ:ETNB) with a Overweight and maintains $29 price target.
Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio (NASDAQ:ETNB) with a Overweight and maintains $29 price target.
HC Wainwright & Co. analyst Ed Arce reiterates 89bio (NASDAQ:ETNB) with a Buy and maintains $29 price target.
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress ...
89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innov...
Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio (NASDAQ:ETNB) with a Overweight and maintains $29 price target.
HC Wainwright & Co. analyst Ed Arce reiterates 89bio (NASDAQ:ETNB) with a Buy and maintains $29 price target.
HC Wainwright & Co. analyst Ed Arce reiterates 89bio (NASDAQ:ETNB) with a Buy and maintains $29 price target.